The NUTRIATE study represents collaboration between CERU and an industry sponsor to investigate a novel molecule to enhance gastric emptying in critically ill patients. Subjects will be recruited in Canada, the US and Australia.

Status of the study: Recruiting

Providing optimal delivery of enteral nutrition (EN) early in the clinical course of critically-ill patients is recognized as an integral component of high quality standard supportive care. Gastric emptying is impeded in 40-60% of ICU patients. This results in an inability to deliver adequate enteral nutrition to our patients, an increase in gastric residual volumes (GRVs), and a potential aspiration of gastric contents. Will repeat doses of GSK962040 enhance gastric emptying and, thereby, increase the delivery of enteral nutrition to mechanically-ventilated critically-ill patients that have conditions which predispose them to delayed gastric emptying.

This trial is registered at ClinicalTrials.gov (NCT01934192).

For more information on this study or research related to motility agents in the treatment of enteral nutrition intolerance, please contact the CERU Project Leader This email address is being protected from spambots. You need JavaScript enabled to view it..